The genetic basis of malignant hyperthermia (MH) is not fully characterised and likely involves more than just the currently classified mutations in the gene encoding the skeletal muscle ryanodine receptor (RYR1) and the gene encoding the α1 subunit of the dihydropyridine receptor (CACNA1S). In this paper we sequence other genes involved in calcium trafficking within skeletal muscle in patients with positive in vitro contracture tests, searching for alternative genes associated with MH. We identified four rare variants in four different genes (CACNB1, CASQ1, SERCA1 and CASQ2) encoding proteins involved in calcium handling in skeletal muscle in a cohort of 30 Australian MH susceptible probands in whom prior complete sequencing of RYR1 and CACNA1S had yielded no rare variants. These four variants have very low minor allele frequencies and while it is tempting to speculate that they have a role in MH, they remain at present variants of unknown significance. Nevertheless they provide the basis for a new set of functional studies, which may indeed identify novel players in MH.
Introduction
Malignant hyperthermia (MH) is an inherited condition characterised by a hypermetabolic response to volatile anaesthetic agents and depolarising muscle relaxants. In a typical case there is escalating CO 2 production and muscle rigidity associated with rapid body temperature elevation, tachycardia, arrhythmias, acidosis and hyperkalaemia. Not all cases are typical and may be suspected with only a few of these signs 1 . Some cases are so severe that even with appropriate treatment, deaths still occur 2 .
The diagnosis of MH is based on clinical suspicion and confirmed by muscle biopsy and contracture testing. In our institution, the in vitro contracture test (IVCT) is performed as per the European protocol 3, 4 . This involves force measurements using bundles of fibres (taken from vastus lateralis in an anaesthetised subject), which are subjected to increasing concentrations of caffeine and halothane in tissue baths. Caffeine is a pharmacological stimulant of calcium release from the sarcoplasmic reticulum (SR) 5 , and muscle exposed to caffeine from persons susceptible to MH has a lower threshold for force generation than those who are not susceptible. In addition, exposure to halothane in normal muscle produces little or no response whereas malignant hyperthermia-susceptible (MHS) muscle generates a more substantial force.
In 1990 the association of RYR1 mutations with MH susceptibility in humans was first published 6, 7 , offering the promise of a less invasive approach to MH testing and diagnosis. More recently, MH families have had variants identified and functionally tested in the α 1 subunit of the dihydropyridine receptor (CACNA1S) 8, 9 , but studies of MH families in Australia and New Zealand 10 , North America 11 , Europe 12 and Great Britain 13 indicate that there are as many as 60% of families without a variant in RYR1 or CACNA1S.
Historical linkage studies to other loci including chromosome 17q (MHS2) [14] [15] [16] , chromosome 7q (MHS3) 17 , and chromosomes 3q 18 , 1q and 5p 19 offer some indication of the genetic diversity of MH and serve to remind us that RYR1 and CACNA1S are not the only genes involved in MH. In addition, there are indications of an MH-like phenotype in CASQ1 knock-out mice 20 and a STAC3 mutation 21,22 associated with a myopathy and MH. Thus previous genetic research, clinical variability, and variability in IVCT response 23 reflect the nature of MH as a disorder with more than one pathway leading to excess calcium in the normally strictly regulated cytoplasm of the skeletal muscle cell.
This study looked for variants in other genes involved in calcium handling in skeletal muscle in MH-susceptible individuals who have no variant in RYR1 or CACNA1S. Specifically, the copy DNA (cDNA) for the remaining subunits of the skeletal muscle L-type voltage-gated calcium channel [CACNA2D1, CACNB1, CACNG1], the proteins responsible for returning calcium to the SR [SERCA1, SERCA2], and the major calcium-binding proteins in the SR [CASQ1, CASQ2] were sequenced. The overall purpose of the study was to identify novel variants for further research into the genetics of MH.
Methods
The entire coding regions of the genes CACNA2D1, CACNB1, CACNG1, SERCA1, SERCA2, CASQ1, CASQ2 were analysed by Sanger sequencing from cDNA obtained from 30 of the probands from our previous RYR1 and CACNA1S mutation detection study 10 in whom no variants were identified. The remaining nine patients in that study had cDNA of inadequate quality to sequence all of the genes and were eliminated from subsequent analysis (probands from families E, J, L, N, V, AF, AO, AP, BF). The samples for genetic analysis were obtained with patient consent and in accordance with Melbourne Health Human Research Ethics Committee (2006.223) approval.
Muscle was collected at biopsy and immediately stabilised with RNALater solution. RNA was extracted from the muscle specimen using TRIzol® reagent (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA) and immediately reverse transcribed to cDNA with Superscript® III Supermix (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA), both according to the manufacturer's instructions. Genomic DNA was extracted from a blood specimen according to the standard protocol of the Victorian Clinical Genetics Service Molecular Genetics Laboratory using a robotic method with Chemagen chemistry (PerkinElmer Inc., Waltham, MA, USA).
The cDNA was amplified twice in overlapping fragments of 400 to 700 base pairs using Hotstar Taq polymerase (Qiagen Pty Ltd, Melbourne, Victoria) and a nested approach. The internal amplification primers were used for sequencing in each direction on an ABI 3730 (Applied Biosystems, ThermoFisher Scientific, Waltham, MA, USA) automated sequencer with Big Dye chemistry (Applied Biosystems, ThermoFisher Scientific, Waltham, MA, USA). Sequencing was read in both forward and reverse directions.
The reference sequences used to design primer pairs were: NM_000722.2 for CACNA2D1, NM_199247.2 for CACNB1 (isoform 2), NM_000727.3 for CACNG1, NM_004320.4 for SERCA1 (isoform a), NM_001681.3 for SERCA2 (isoform a), NM_001231.4 for CASQ1, NM_001232.3 for CASQ2.
Sequenced nucleotides were numbered according to these reference sequences, except for CACNA2D1, which was numbered according to XM_005250570.1 instead. Alternately spliced exons 7 and 8 of CACNB1 isoforms were sequenced directly from genomic DNA (gDNA) from the same probands in whom the alternate exon splicing was observed. All cDNA sequence variants resulting in an amino acid substitution were confirmed by sequencing of the relevant exon in gDNA extracted from the blood sample from the same proband.
The minor allele frequency (MAF) of each observed variant in the Exome Aggregation Consortium (ExAC) 24 was used to differentiate between polymorphisms (common DNA changes causing an amino acid substitution but not segregating with MH in the population) and variants rare enough to have a possible association with MH. A MAF of 0.001 was used as the cut-off. PolyPhen2 (Polymorphism Phenotyping v2), PhastCons (Phylogenetic Analysis with Space/Time Models Conservation) and GERP++ (genomic evolutionary rate profiling) scores predicting functionality and conservation across species were generated by the SeattleSeq Annotation Server 25 for each of the observed variants.
PolyPhen2 is a tool which predicts the possible impact of an amino acid substitution on the structure and function of a human protein using physical and comparative considerations, giving a score between 0 (benign) and 1 (probably damaging) 26 . GERP++ score is a measure of evolutionary constraint derived by aligning multiple mammalian genomes 27 . Negative scores imply a relative lack of conservation and the more positive the score, the stronger the conservation across species, implying a region of the protein which is likely to be functionally important. PhastCons scores are based on conservation of amino acids in multiple alignments, given a phylogenetic tree, with scores between 0 (little conservation) and 1 (complete conservation) 28 .
The results from IVCT were classified into NT, MIN, MOD and MAX on the basis of the strength of the response to either halothane or caffeine. These classifications were used because IVCT response has been associated with type of genetic change 10, 29 . A response of less than 0.2g at 2% halothane or 2 mM caffeine was graded as NT (not achieving threshold), 0.2g to 0.29g as MIN (minimal), 0.3g to 0.99g as MOD (moderate) and 1.0g or greater as MAX (maximal). The Clinical Grading Scale (CGS) 30 was determined where possible from information recorded at the time of the suspected MH reaction in the proband or nearest relative in the pedigree.
Results
The cohort for this study comprised twenty-four MHS hc (responding to halothane and caffeine), four MHS h (responding to halothane but not caffeine) and two MHS c (responding to caffeine but not halothane) unrelated individuals, as determined by their response to IVCT, with no mutation or rare variant detected after complete Sanger sequencing of both RYR1 and CACNA1S. Table 1 provides a summary of the IVCT findings, CGS and the non-synonymous nucleotide changes observed, using the same family designations as in our previous study 10 . A total of four novel variants were detected in four different genes (CACNB1 c.467T>C, CASQ1 c.1090G>A, CASQ2 c.1131A>T, SERCA1 c.1106T>C), all from probands with an MHS hc response to IVCT. In addition, two common polymorphisms were detected (CACNG1 c.586G>A, CASQ2 c.196A>G), in 5 and 10 probands respectively.
Twenty-six probands had no non-synonymous changes or polymorphisms only. Table 2 shows the observed variants, their MAF, the amino acid substitution associated with the base pair alteration along with predicted pathogenicity and conservation scores.
Discussion
MH is generally regarded as a condition where the primary defect is an excessive proclivity of the skeletal muscle ryanodine receptor type 1 to open, releasing calcium from SR into the cytoplasm 31 in the presence of triggering anaesthetic agents, with gain of function mutations in RYR1 being the most common underlying cause. Mutations in the α 1 subunit of the skeletal muscle L-type (1,4dihydropyridine-sensitive) calcium channel can produce an identical phenotype. However, complete sequencing of both the RYR1 and CACNA1S genes in a cohort of 62 consecutive, unrelated IVCT-confirmed MH probands in our previous study yielded mutations or rare variants in only 23 (37%) of these families 10 leaving the greater proportion genetically undetermined. Accordingly, we chose to expand the search by completely sequencing the coding regions of a further seven genes known to be associated with calcium handling in skeletal muscle SR (CACNA2D1, CACNB1, CACNG1, SERCA1, SERCA2, CASQ1, CASQ2) in 30 of the probands from that Table 1 IVCT results and CGS scores versus variants and polymorphisms observed in each proband study, in whom no rare variant was observed with complete sequencing of the RYR1 and CACNA1S genes. This series of genes encode the proteins that constitute the remaining subunits of the L-type calcium channel, the ATPases responsible for transport of calcium back into SR, and the major calcium binding proteins within SR of skeletal muscle. The current study found rare variants in four of the seven genes sequenced: one in each of CACNB1, CASQ1, SERCA1 and CASQ2; each observed in a single, different MHS hc proband. All four variants are rare, appearing in the ExAC database 24 at a MAF of 0.00067 to 0.00002 (Table 2) , with the CACNB1 variant being most commonly observed. The CACNB1 c.467T>C (Val156Ala) variant has a high PolyPhen2 score and occurs in a very highly conserved locus, indicating that this region is functionally important and therefore this variant may have a role in the pathogenesis of MH in this family. The CASQ1 c.1090G> A (Glu364Lys) variant yields a slightly more moderate PolyPhen2 score but does occur in a conserved locus, suggesting that it may also have a role in MH. While the SERCA1 c.1106T>C (Ile369Thr) variant gives a less convincing PolyPhen2 score, it too is located in a conserved locus. The least convincing of the four variants is the CASQ2 1131A>T (Glu377Asp) variant with a low PolyPhen2 score and a location in a poorly conserved locus, and is thus less likely to be MH causative on its own, but could have a role in influencing the phenotype. However, this assessment must be considered preliminary, tempered by the known difficulty in ascribing pathogenicity with predictive software in conditions based around modified ion channels 33 . Unfortunately, no other family members from these four families have come forward for IVCT to date, preventing assessment of concordance of the variants with MH phenotypes, and in turn leaving no option other than functional characterisation of the variants in an appropriate biological model 34 at a later date.
The skeletal muscle L-type (1,4-dihydropyridine-sensitive) calcium channel is made up of five subunits in a 1:1:1:1:1 stoichiometric ratio with the α 1S , β 1 , α 2 plus δ, and the γ proteins encoded by the CACNA1S, CACNB1, CACNA2D1, and CACNG1 genes, respectively. This complex functions as the plasma membrane voltage sensor in excitation-contraction (EC) coupling and is directly responsible for triggering the opening of the SR ryanodine receptor channels via a physical interaction of the II-III loop of the α 1S subunit with the closely apposed ryanodine receptor, in response to transverse tubule depolarisation 35 . Entry of calcium through the L-type calcium channel α 1S subunit is not required to open the ryanodine receptor in skeletal muscle-unlike the situation in cardiac muscle 31 -but there is ample evidence that this inward current does occur and may be responsible for the calcium entry known as excitation-coupled calcium entry (ECCE) in skeletal muscle 36 . In addition, there is both orthograde and retrograde modulation of the sensitivity of both L-type calcium channel entry and the release of calcium from SR through the ryanodine receptor 31 . These properties make the components of the L-type calcium channel potential candidates for involvement in the pathophysiology of MH 37 .
The skeletal muscle β 1 protein encoded by the CACNB1 gene attaches to the I-II helix (loop) of the α 1 subunit in the cytoplasm of skeletal muscle. Its functions include the shaping of channel inactivation, increasing peak L-type calcium current, controlling the alpha-1 subunit membrane targeting, and shifting the voltage dependence of activation and inactivation 38 . Mutations in CACNB1 may increase RyR1 response to dihydropyridine receptor stimulation 39 . The skeletal muscle γ protein subunit is encoded by the CACNG1 gene and increases the voltage-sensitivity of inactivation, calcium influx and calcium release in EC coupling 38 . The CACNB1 and CACNG1 genes are both located on chromosome 17q in the region identified in early MH chromosome linkage studies 14 . The α 2 and δ subunits are both encoded by the CACNA2D1 gene on chromosome 7. Post-translational cleavage produces the two proteins which act as important determinants of the specific activation properties of L-type calcium current, shifting the skeletal muscle L-type calcium channel from a slow activating to a fast activating configuration 38 .
Calsequestrin is a linear polymer located in the SR. It is stabilised by calcium and able to regulate RyR1 when polymerised 40, 41 . The monomeric form occurs when the calcium levels in the SR fall below physiological levels and it is not an effective regulator of RyR1 in this state 41 . Calsequestrin forms a complex with triadin, junctin, and RyR1 and it is this complex which regulates RyR1 40, 42 . CASQ1 is the predominant or only calsequestrin isoform in fast twitch fibres of skeletal muscle, where it acts as the major calcium buffer and store 41 . At high SR calcium concentrations it enhances the release of calcium via RyR1, whereas at low SR calcium concentrations it protects the SR from further calcium depletion 40 . This retrograde signalling occurs through an interaction with junctin 42 . Ablation of CASQ1 results in remodelling of the EC coupling apparatus and functional changes, which in male mice causes an increase in the rate of spontaneous mortality and susceptibility to trigger MH-like lethal episodes in response to halothane and heat stress 43 . In a study by Zhao et al 44 a significant elevation in store-operated calcium entry (SOCE) occurred in skeletal muscle with CASQ1 knockdown. This was accompanied by alteration of calcium release from SR and sensitivity of SOCE to elevated temperature. The study suggests that CASQ1 likely participates in maintaining the retrograde regulation of SOCE in skeletal muscle either in parallel with or as part of its function in calcium buffering within the SR. The authors suggest that one potential mechanism for the MH-like symptoms observed in the CASQ1 knockout mice may be via calcium entry through the SOCE pathway 44 . SERCA (sarco/endoplasmic reticulum Ca++-ATPase) is the major protein responsible for calcium reuptake into skeletal muscle SR against the large concentration gradient. SERCA1 is the predominant or only isoform in fast twitch fibres 45, 46 . Mutations in the gene for this protein are associated with Brody disease 47 , manifest by muscle stiffness and inability to relax after exercise 48 . Structure-function relationships of SERCA have been examined using single amino acid substitution to interfere with calcium transport back into the SR 48 and while no association with MH has been noted it is possible that a defect in SERCA1 that impairs uptake into the SR could produce the rigidity and hypermetabolism associated with MH, and a variant resulting in an increase in the native leak of calcium out of SR via SERCA may have similar effects 46 .
Although CASQ2 and SERCA2 are generally considered in a cardiac muscle context where they are the predominant forms, they are also present in significant quantities in slow twitch (type 1) skeletal muscle fibres. Type 1 fibres contain five-fold more CASQ2 and three-fold less CASQ1 than type 2 fibres 49 , indicating that it is the predominant isoform in slow twitch fibres. Similarly SERCA2 is the predominant form in type 1 fibres 49 . Additionally, human type 1 fibres have a slightly lower endogenous SR calcium content but at a greater proportion of maximal SR content than type 2 fibres. SERCA2 in type 1 muscles is active at lower myoplasmic calcium concentrations but displays a slightly lower maximal rate of calcium transfer into the SR. Endogenous leak of calcium out of the SR is two-fold greater in type 1 fibres than type 2 fibres. While it is clear that calcium handling is different in fast and slow fibres, there is little available information to indicate whether MH is a condition of fast twitch fibres only, slow twitch fibres only or both. Accordingly we chose to sequence CASQ2 and SERCA2 in addition to their fast twitch muscle fibre isoforms.
The features of catecholaminergic polymorphic ventricular tachycardia (CPVT) in cardiac muscle in many ways parallel those of MH 50 , leading them to be both described as couplonopathies 31 . Specifically, defects in RYR2 and CASQ2 (the genes encoding cardiac muscle functional equivalents of the skeletal muscle isoforms RyR1 and CASQ1) have been shown to be responsible for CPVT. The pathophysiology of this syndrome is also a defect in calcium regulation in cardiac muscle 51 . Recently, mutations in CACNA2D1 have been associated with Brugada syndrome 52 and short QT syndrome 53 in cardiac muscle, conditions that bear similarities to CPVT.
Several of the genes sequenced in the study are known to undergo alternate splicing to produce subtly different isoforms. The reference sequences used to design primers for polymerase chain reaction amplification of cDNA in this study were chosen to represent the isoforms expressed predominantly in adult skeletal muscle, and to avoid known alternately spliced exons. Isoform 2 of CACNB1 (NM_199247.2)
is the predominant form in skeletal muscle 45 , which includes exon 7 but not exon 8, but is otherwise identical to isoform 3. However, there was clear evidence of both exons in some probands, which indicates the expression of isoform 1 or 3 or both. The alternately spliced exons were sequenced separately from gDNA in these cases. Isoform (a) was chosen for both SERCA1 and SERCA2 45 . Interestingly, while there appears to be only one known isoform of CACNA2D1, all 30 probands yielded sequencing that instead conformed to XM_005250570.1, with an extra exon between 18 and 19. Exon 23 was excluded when compared with the known reference sequence NM_000722.2. Both changes are in-frame.
This study probably represents the maximum extent to which Sanger sequencing alone can be used for mutation detection in MH. It required a considerable body of work, as 39 amplicons were needed for each proband for complete sequencing of the coding regions of the seven genes studied, and a total of 77 amplicons per proband when the prior sequencing of RYR1 and CACNA1S is considered 10 . The use of cDNA reduced the number of amplicons required for complete sequencing of a gene four-fold compared to Sanger sequencing from gDNA. However it does introduce some difficulties, the most notable being the error-prone nature of the viral reverse transcriptase required to make cDNA from RNA and the instability of the RNA starting material 32 . While we confirmed all variants observed in cDNA in a second gDNA sample, there were nine probands from our previous study 10 in whom RNA wasn't of sufficient quality to make cDNA that could be reliably sequenced. These probands were eliminated from the current analysis. On the other hand, the use of cDNA is a major strength as it allows access to the specific transcription isoforms actually expressed in skeletal muscle for the transcripts with multiple splice forms. Targeted next generation sequencing or whole exome sequencing is becoming a much more viable option in terms of cost, technical input and time required than the Sanger sequencing of cDNA for multiple genes.
Combining the results of the current study with our previous study of RYR1 and CACNA1S 10 , we have observed variants in 27 of the 53 probands (51%) in whom cDNA was of high enough quality to sequence all nine genes in this Australian cohort.
In conclusion, we have identified four rare variants in four different genes (CACNB1, CASQ1, SERCA1 and CASQ2) encoding proteins involved in calcium handling in skeletal muscle in a cohort of 30 Australian MHS probands in whom prior complete sequencing of RYR1 and CACNA1S had yielded no rare variants. These four variants have very low MAFs and while it is tempting to speculate that they have a role in MH, they remain at present variants of unknown significance. Nevertheless they provide the basis for a new set of functional studies which may indeed identify novel players in MH.
